Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Curreen Capital Christian Ryther | “Fortrea helps its biotech and pharmaceutical customers to run clinical trials with the goal of receiving marketing authorization in the U.S. and other countries. Fortrea helps design th” | NEUTRAL | Q2 2026 Aug 10, 2026 | View Pitch |
Curreen Capital Christian Ryther | “Fortrea helps its biotech and pharmaceutical customers to run clinical trials with the goal of receiving marketing authorization in the U.S. and other countries. For...” | BULL | Q2 2026 Aug 10, 2026 | View Pitch |
Curreen Capital Christian Ryther | “Spun off from Labcorp in 2023, the clinical trial provider is working through a business turnaround. Its current stock price represents an exceptionally favorable upside compared to its potential downside.” | BULL | Q1 2026 Apr 29, 2026 | View Pitch |
Curreen Capital Christian Ryther | “Fortrea is an example of our “Crazy Cheap” strategy: buying excellent businesses priced as if their current struggles will last forever. These are ugly ducklings that are especially unpopular, and their stock prices have often fallen hard for months. Fortrea faced headwinds, with weak financial results, the loss of a star CEO, and swirling fears about changing US health policy. “Crazy Cheap” stocks like Fortrea are often going through a painful period, but their low price creates an extremely attractive upside-to-downside. There is still downside risk, but it is dwarfed by the probability and magnitude of the upside. Overall, buying good businesses at “Crazy Cheap” prices has worked well for us. BSD Analysis: Fortrea Holdings is signaling a significant recovery in 2026, recently upgraded by analysts following a surge in net bookings and a book-to-bill ratio exceeding 1.23 times. The company is successfully navigating its post-spin-off period by securing robust demand from both large pharmaceutical firms and emerging biotech players. For 2026, the investment narrative is built on projected net savings of $40 million to $50 million and a quickening biopharma development cycle that is driving higher billable hours. While historical project blends have previously pressured margins, the company's shift toward newer, higher-margin Phase I clinical pharmacology services is providing a turning point for profitability. Management's progress on debt reduction and operational streamlining has rebuilt investor confidence after a period of choppy share price performance. With the stock currently trading at a significant discount to its intrinsic fair value, Fortrea offers a compelling "valuation reset" opportunity in the clinical research space.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Voya MI Dynamic Small Cap Fund (formerly Voya Small Company Fund) Voya Investments, LLC | “The overweight position to healthcare stock Fortrea Holdings Inc. (FTRE) had a positive impact on performance. FTRE ranked in the top 50% of the universe and had attractive factors embedded in the stock, which led to the overweight holding. During the quarter, the stock rose boosted by strong net bookings. BSD Analysis: Fortrea is CRO infrastructure carved out of a larger system and still finding its independent footing. Drug development doesn't stop when funding tightens — it just shifts toward operators that can execute cleanly. Investors treat Fortrea like a broken spin and miss the embedded relationships and trial backlog. Margin pressure reflects transition noise more than structural weakness. Scale and regulatory credibility matter more than branding in clinical research. As operations stabilize, earnings power becomes clearer. This is life-sciences plumbing rebuilding credibility, not a melting ice cube.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Curreen Capital Christian Ryther | “Fortrea helps its biotech and pharmaceutical customers to run clinical trials with the goal of receiving marketing authorization in the U.S. and other countries. Fortrea helps design the trials, recruit investigators and participants, prepare data for regulatory review, and other tasks needed to win the authorization to market new treatments. The company spun out of Labcorp in June 2023, and is attempting to turn around the business. Fortrea currently trades at an attractive upside-to-downside ratio. BSD Analysis: Fortrea's CRO turnaround offers asymmetric upside as restructuring stabilizes operations post-spin. With improving client retention, margin recovery, and deleveraging, shares could re-rate toward peer multiples (~13x EBITDA).” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Curreen Capital Christian Ryther | “Fortrea is a contract research organization (CRO), which means they run clinical trials to test treatments that pharmaceutical companies are trying to get approved for use in patients. I have been following Fortrea since it spun out of Labcorp in June 2023. Back then, Fortrea seemed like an exciting, fast growing business earning good returns on capital, with a star CEO who had a reputation for running (and selling) a similar business. Things have fallen apart since then… Compared to the exciting period after COVID, fervor for new drug research has declined. Less money has flowed to biotech companies, who hire CROs to help run the clinical trials they need in order to market their therapies. In addition to this industry-wide headwind, Fortrea has gone through the expensive process of setting up its own IT systems and operations separate from Labcorp. Fortrea also has a decent amount of debt, which is common in spinoffs. All in, this once exciting business ran into an industry slowdown, increased spending on stand-up costs, and still had all that debt to deal with. Earnings turned to losses, the stock price dropped and kept dropping, and as of mid-May the star CEO was out. Okay…what is there to like about this situation? The positives are that Fortrea has been winning new clinical trials and growing its backlog. The company has nearly completed the stand-up of its own systems and separation from Labcorp's – which means they can stop paying for two systems, reducing expenses. The financial picture is ugly, but I think that it is improving and that the company will avoid a painful financial restructuring. Also, the stock is priced for disaster. On the other side of the current unpleasantness is a good business in a good industry. Running clinical trials is not capital intensive – the drug company customer supplies the medicine, and the contract research organization finds investigators (doctors) who generally see the trial participants in the doctors' own offices. While this capital-light model allows contract research organizations to earn good returns on capital, there are barriers to entry for would-be competitors. CROs have to know the science and regulations involved in getting drugs approved in different jurisdictions worldwide, they need to know and have a good reputation with doctors who can work on the clinical trials and bring in patients. And in addition to this know-how and know-who, drug companies need to feel confident that they are hiring a CRO who will give them a solid shot at getting their drug approved for use. Getting a new drug approved is a long and expensive process – and the drug company's main goal is to maximize the time that their therapy is on-market and patent-protected. Anything that delays FDA approval—be it signing up investigators, recruiting and retaining patients, analyzing and presenting data, and generally jumping through regulatory hoops—eats into that patent-protected period and costs Fortrea's customers a lot of money. Going with a lower priced new entrant, vs going with Fortrea or one of the other large players with a track record, is risky for the pharmaceutical company customer (and introduces career risk for the individual making the choice) because the new entrant may delay—by months, years, or even permanently—approval by the FDA and other regulators. New drug research should continue as long as patents are legally protected and valuable, and the aging global population increases demand for new treatments. I do not see the current political climate changing either of these long-term drivers. Increasing demand is met by a limited supply of CROs with a track record, which sets the industry up for continued growth at high returns on capital. Historically, CROs have used their free cash flow to grow and to buy back stock. While turnarounds often take more time than I would like, Fortrea should make it back to being a growing business earning high returns on capital, and that might even earn it an exciting earnings multiple. I think they are on track. We paid $5.85 per share for our position in Fortrea, which was about 4.5% of the fund. I thought that price was extremely cheap, though the stock has since dropped further. BSD Analysis: Fortrea is a distressed-valuation CRO with durable long-term fundamentals obscured by temporary separation costs, biotech funding cyclicality, and inherited leverage. Its growing backlog demonstrates relevance and customer trust, while completion of the Labcorp separation should unlock meaningful cost relief. CROs historically generate high ROIC through regulatory expertise and reputation-based moats—advantages Fortrea still possesses. Shares trade at crisis-level multiples inconsistent with mid-cycle earnings power. If biotech funding stabilizes and internal execution improves, the stock could re-rate significantly. Key risks include leverage, execution, and industry budget cycles.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
